Design of A New Candidate BACE-1 Inhibitor with Computational Chemistry Method in The Treatment of Alzheimer's Disease

Öz

In recent years, the incidence of Alzheimer's disease has increased with the increase in the elderly population all over the world. Alzheimer's disease is related to the abnormality and disorder of more than one system, its pathogenesis is complex. Therefore, there is no ideal drug currently used to prevent and treat Alzheimer's, and many studies on Alzheimer's are ongoing. In the related study, docking studies were performed with the 2WJO pdb id coded crystal structure of the BACE-1 enzyme, which is associated with Alzheimer's disease, with the Lupeol molecule and 32 newly designed Lupeol derivatives using Autodock Vina software. In this context, first of all, conformers and geometric optimizations of Lupeol and its derivatives were performed with Spartan'16 software. On the other hand, visualizations and interaction maps between protein and ligands were made by Discovery Studio Visualer software. As a result of docking studies, four molecules as L-28, L-23, L-27 and L-31 with higher binding energies than Lupeol structures are determined. In the derivatization studies, it has been determined that the design of more hydrophilic structures for the active site gives better binding energy. Experimental examination of the relevant molecules is recommended.

Anahtar Kelimeler

• Alzheimer
• Docking
• Lupeol
• BACE-1
• AutoDock Vina

Moleküler Kenetlenme Simülasyonları ile Yeni Aday BACE-1 İnhibitörü Tasarımı

Öz

Dünyadaki yaşlı nüfusta görülen artış Alzheimer hastalığının daha yaygın bir hale gelmesine neden olmuştur. Alzheimer hastalığı birden fazla sistemin anormalliği ve bozukluğu ile ilgilidir, patogenezi karmaşık olası sebebi ile önlemek ve tedavi etmek için şu an kullanılan ideal bir ilaç yoktur ve ilaç araştırmaları devam etmektedir. İlgili çalışmada, Alzheimer hastalığı ile ilişkili olan BACE-1 enziminin 2WJO pdb id kodlu kristal yapısı ile lupeol molekülü ve 32 adet yeni tasarlanan Lupeol türevi ile Autodock Vina yazılımı kullanılarak kenetlenme çalışmaları yapılmıştır. Bu bağlamda öncelikle, Lupeol ve türevlerinin konformerleri ve geometrik optimizasyonları Spartan’16 yazılımı ile gerçekleştirilmiştir. Discovery Studio Visualer yazılımında ise görselleştirmeler yapılarak protein ve ligantlar arasındaki etkileşim haritaları çizilmiştir. Kenetlenme çalışmaları sonucunda, Lupeol yapılarından daha yüksek bağlanma enerjilerine sahip L-28, L-23, L-27 ve L-31 olmak üzere dört molekül belirlenmiştir. Yapılan türevlendirme çalışmalarında aktif bölge için daha hidrofilik yapıların tasarımının daha iyi bağlanma enerjisi verdiği tespit edilmiştir. İlgili moleküllerin deneysel olarak incelenmesi önerilmektedir.

Anahtar Kelimeler

• Alzheimer
• Kenetlenme
• Lupeol
• BACE-1
• AutoDock Vina

Kaynakça

1. [1] J. P. S. Ferreira, H. M. T. Albuquerque, S. M. Cardoso, A. M. S. Silva, and V. L. M. Silva, "Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)," Eur. J. Med. Chem., vol. 221, pp. 113492, 2021.
2. [2] M. T. Gabr and M. S. Abdel-Raziq, "Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors," Bioorg. Chem., vol. 80, pp. 245–252, 2018.
3. [3] Z. Sang, K. Wang, P. Zhang, J. Shi, W. Liu, and Z. Tan, "Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease," Eur. J. Med. Chem., vol. 180, pp. 238–252, 2019.
4. [4] A. Kumar, G. Srivastava, and A. Sharma, "A physicochemical descriptor-based method for effective and rapid screening of dual inhibitors against BACE-1 and GSK-3β as targets for Alzheimer's disease," Comput. Biol. Chem., vol. 71, pp. 1–9, 2017.
5. [5] X. J. Zhao, D. M. Gong, Y. R. Jiang, D. Guo, Y. Zhu, and Y. C. Deng, "Multipotent AChE and BACE-1 inhibitors for the treatment of Alzheimer's disease: Design, synthesis and bio-analysis of 7-amino-1,4-dihydro-2H-isoquilin-3-one derivatives," Eur. J. Med. Chem., vol. 138, pp. 738–747, 2017.
6. [6] J. K. Dhanjal, S. Goyal, S. Sharma, S. Hamid, and A. Grover, "Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer's plaque pathology," Biochem. Biophys. Res. Commun., vol. 443, pp. 1054–1059, 2014.
7. [7] A. J. Doig, and P. Derreumaux, "Inhibition of protein aggregation and amyloid formation by small molecules," Curr. Opin. Struct. Biol., vol. 30, pp. 50–56, 2015.
8. [8] C. Bohm, F. Chen, J. Sevalle, S. Qamar, R. Dodd, Y. Li, G. Schmitt-Ulms, P. E. Fraser, and P. H. St George-Hyslop, "Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways," Mol. Cell. Neurosci., vol. 66, pp. 3–11, 2015.

9. [9] P. Picón-Pagès, J. Bonet, J. García-García, J. Garcia-Buendia, D. Gutierrez, J. Valle, C. E. S. Gómez-Casuso, V. Sidelkivska, A. Alvarez, A. Perálvarez-Marín, A. Suades, X. Fernàndez-Busquets, D. Andreu, R. Vicente, B. Oliva, and F. J. Muñoz, "Human albumin impairs amyloid β-peptide fibrillation through its C-terminus: From docking modeling to protection against neurotoxicity in Alzheimer's disease," Comput. Struct. Biotechnol. J., vol. 17, pp. 963–971, 2019.
10. [10] J. Janssens, B. Hermans, M. Vandermeeren, E. Barale-Thomas, M. Borgers, R. Willems, G. Meulders, C. Wintmolders, D. van den Bulck, A. Bottelbergs, L. Ver Donck, P. Larsen, D. Moechars, W. Edwards, M. Mercken, and B. van Broeck, "Passive immunotherapy with a novel antibody against 3pE-modified Aβ demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice," Neurobiol. Dis., vol. 154, p. 105365, 2021.
11. [11] S. Das, T. Majumder, A. Sarkar, P. Mukherjee, and S. Basu, "Flavonoids as BACE-1 inhibitors: QSAR modelling, screening and in vitro evaluation," Int. J. Biol. Macromol., vol. 165, pp. 1323–1330, 2020.
12. [12] P. Gürbüz, A. H. Dokumacı, M. G. Gündüz, C. Perez, F. Göger, M. Y. Paksoy, M. B. Yerer, and L. Ömür Demirezer, "In vitro biological activity of Salvia fruticosa Mill. Infusion against amyloid β-peptide-induced toxicity and inhibition of GSK-3β, CK-1δ, and BACE-1 enzymes relevant to Alzheimer's disease," Saudi Pharm. J., vol. 29, pp. 236–243, 2021.
13. [13] D. Huang, Y. Liu, B. Shi, Y. Li, G. Wang, and G. Liang, "Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking," J. Mol. Graph. Modell., vol. 45, pp. 65–83, 2013.
14. [14] G. Ribaudo, P. Coghi, E. Zanforlin, B. Y. K. Law, Y. Y. J. Wu, Y. Han, A. C. Qiu, Y. Q. Qu, G. Zagotto, and V. K. W. Wong, "Semi-synthetic isoflavones as BACE-1 inhibitors against Alzheimer's disease," Bioorg. Chem., vol. 87, pp. 474–483, 2019.
15. [15] Lahiri DK, et al. Lessons from a BACE1 inhibitor trial: off-site but not off base. Alzheimers Dement. 2014;10(5 Suppl):S411–9.
16. [16] Das, B., Yan, R. A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment. CNS Drugs 33, 251–263 (2019). https://doi.org/10.1007/s40263-019-00613-7
17. [17] Y. Gao, X. Wang, and C. He, "An isoflavonoid-enriched extract from Pueraria lobata (kudzu) root protects human umbilical vein endothelial cells against oxidative stress induced apoptosis," J. Ethnopharmacol., vol. 193, pp. 524–530, 2016.
18. [18] Z.-B. Wang, B. B. Chen, L. Luo, and J. K. Yan, "Fractionation, physicochemical characteristics and biological activities of polysaccharides from Pueraria lobata roots," J. Taiwan Inst. Chem. Eng., vol. 67, pp. 54–60, 2016.
19. [19] M. Saleem, "Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene," Cancer Lett., vol. 285, pp. 109–115, 2009.
20. [20] A. K. Srivastava, S. Mishra, W. Ali, and Y. Shukla, "Protective effects of lupeol against mancozeb-induced genotoxicity in cultured human lymphocytes," Phytomedicine, vol. 23, pp. 714–724, 2016. [21] M. Ohno, E. A. Sametsky, L. H. Younkin, H. Oakley, S. G. Younkin, M. Citron, R. Vassar, and J. F. Disterhoft, "BACE-1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease," Neuron, vol. 41, pp. 27–33, 2004.
21. [22] J. Kong, C. A. White, A. I. Krylov, C. D. Sherrill, R. D. Adamson, T. R. Furlani, M. S. Lee, A. M. Lee, S. R. Gwaltney, T. R. Adams, C. Ochsenfeld, A. T. B. Gilbert, G. S. Kedziora, V. A. Rassolov, D. R. Maurice, N. Nair, Y. Shao, N. A. Besley, P. E. Maslen, J. P. Dombroski, H. Daschel, W. Zhang, P. P. Korambath, J. Baker, E. F. C. Byrd, T. V. Voorhis, M. Oumi, S. Hirata, C. P. Hsu, N. Ishikawa, J. Florian, A. Warshel, B. G. Johnson, P. G. M. Gill, M. H. Gordon, and J. A. Pople, "Q-Chem 2.0: a high‐performance ab initio electronic structure program package," J. Comput. Chem., vol. 21, pp. 1532–1548, 2000.
22. [23] J. J. P. Stewart, "Application of the PM6 method to modeling the solid-state," J. Mol. Model., vol. 14, pp. 499–535, 2008.
23. [24] J. J. P. Stewart, "Application of the PM6 method to modeling proteins," J. Mol. Model., vol. 15, p. 765, 2009.
24. [25] An accurate and universal protein-small molecule batch docking solution using Autodock Vina, Results in Engineering, 19, 101335, 2023, https://doi.org/10.1016/j.rineng.2023.101335, Xinhao Che and Qilei Liu and Lei Zhang
25. [26] O. Trott and A. J. Olson, "AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading," J. Comput. Chem., vol. 31, pp. 455–461, 2010.
26. [27] Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San Diego, CA, USA: Dassault Systèmes, 2016.
27. [28] K. Youn and M. Jun, "Biological evaluation and docking analysis of potent BACE1 inhibitors from Boesenbergia rotunda," Nutrients, vol. 11, p. 662, 2019.